NCT07024641招募中1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 22
- 主要终点
- SAD and MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hepatitis B envelope antigen (HBeAg) negative chronic HBV infection for ≥ 6 months, defined as presence of Hepatitis B surface antigen (HBsAg) in serum for ≥ 6 months.
- •Serum HBsAg concentration between ≥ 100 international units per milliliter (IU/mL) and 2000 IU/mL at screening.
- •Currently on stable dose of nucleot(s)ide analogues (NAs) (≥ 6 months) and expected to continue while participating in the study, or are not received NAs.
- •Have serum HBV deoxyribonucleic acid (DNA) concentration ≤ 50 IU/mL at screening (for those who are on NAs); or have serum HBV DNA concentration ≤ 2000 IU/mL at screening (for those who are NOT on NAs).
- •Male participants must refrain from donating spermatozoa and agree to use highly effective contraception.
- •Female participants must not be pregnant, or breastfeeding; either should not be a woman of childbearing potential (WOCBP) or if WOCBP should use highly effective contraceptive methods.
排除标准
- •Positive for co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and/or hepatitis D virus (HDV) at screening.
- •Participants that weigh less than 50 kilograms (kg) and/or have a body mass index (BMI) less than 18.
- •History of documented liver cirrhosis at screening. Patients under liver cirrhosis evaluation at screening will not be eligible until cirrhosis is ruled out.
- •Liver stiffness > 8 kilopascal (kPa) at screening.
- •History of chronic liver disease from another cause, immune complex disease, or autoimmune diseases that in the opinion of the investigator would preclude participation.
- •Family history of hepatocellular carcinoma (HCC).
- •Alpha fetoprotein > 20 nanograms per milliliter (ng/mL).
- •Presence of a liver imaging reporting and data system (LI-RADS) 4 or 5 liver lesion on imaging 12 months prior to Screening OR, LI-RADS-US findings of US-3 grade on imaging 12 months prior to Screening, OR LIRADS-US grade 3 done prior to the D1 infusion visit, if prior LI-RADS or LI-RADS-US results are not available at Screening.
- •History of hematopoietic stem cell transplant or solid organ transplant.
- •Receipt of anti-HBV monoclonal antibody (mAb)/pAb therapy of any kind in the past (including hepatitis B immunoglobulin [HBIG]).
- •History of cardiovascular disease (e.g., coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long QT syndrome). Stable hypertension is allowed.
- •Malignancy diagnosed and/or treated within 5 years prior to Screening, and/or with ongoing treatment for malignancy, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.
- •Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors, or anti-platelet agents like clopidogrel).
- •Male participants with a corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) and female participants with QTcF > 470 msec on ECG recorded at screening. if the participant has evidence of an intraventricular conduction delay, defined as QRS interval greater than 110 msec, a QTcF is > 500 msec for both males and females will be excluded.
- •Known hypersensitivity to any GIGA-2339 excipients or any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (nonactive hay fever is acceptable), or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates participation.
- •Received or will receive live-attenuated virus vaccinations such as measles, mumps, rubella or varicella within 4 weeks before and up to three months after administration of investigational product (IP).
研究组 & 干预措施
Part 2: Multiple Ascending Dose (MAD)
Experimental
Participants will receive multiple IV infusions of either GIGA-2339 or placebo, once every 4 weeks, at a dose determined in Part 1.
干预措施: GIGA-2339 (Drug)
Part 1: Single Ascending Dose (SAD)
Experimental
Participants will receive a single IV infusion of either GIGA-2339 or placebo in ascending doses on Day 1.
干预措施: Placebo (Drug)
Part 1: Single Ascending Dose (SAD)
Experimental
Participants will receive a single IV infusion of either GIGA-2339 or placebo in ascending doses on Day 1.
干预措施: GIGA-2339 (Drug)
Part 2: Multiple Ascending Dose (MAD)
Experimental
Participants will receive multiple IV infusions of either GIGA-2339 or placebo, once every 4 weeks, at a dose determined in Part 1.
干预措施: Placebo (Drug)
结局指标
主要结局
SAD and MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
时间窗: SAD: Up to Day 105; MAD: Up to Day 245
次要结局
- SAD and MAD: Maximum Serum Concentration (Cmax) of GIGA-2339(SAD: Pre-dose and at multiple timepoints post-dose up to Day 105; MAD: Pre-dose and at multiple timepoints post-dose up to Day 245)
- SAD and MAD: Area Under the Concentration Time Curve (AUC) from 0 to the Last Quantifiable Concentration (AUC0-t) of GIGA-2339(SAD: Pre-dose and at multiple timepoints post-dose up to Day 105; MAD: Pre-dose and at multiple timepoints post-dose up to Day 245)
- SAD: AUC From 0 to Infinity (AUC0-∞) of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 105)
- SAD: Dose Normalized Maximum Serum Concentration (DN_Cmax). of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 105)
- SAD: Dose Normalized AUC From 0 to the Last Quantifiable Concentration (DN_AUC0-t) of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 105)
- SAD: Dose Normalized AUC From 0 to Infinity (DN_AUC0-∞) of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 105)
- SAD and MAD: Time to Obtain Maximum Concentration (Tmax) of GIGA-2339(SAD: Pre-dose and at multiple timepoints post-dose up to Day 105; MAD: Pre-dose and at multiple timepoints post-dose up to Day 245)
- SAD and MAD: Terminal Half-Life (t1/2) of GIGA-2339(SAD: Pre-dose and at multiple timepoints post-dose up to Day 105; MAD: Pre-dose and at multiple timepoints post-dose up to Day 245)
- SAD and MAD: Volume of Distribution (Vz) of GIGA-2339(SAD: Pre-dose and at multiple timepoints post-dose up to Day 105; MAD: Pre-dose and at multiple timepoints post-dose up to Day 245)
- SAD and MAD: Systemic Clearance (CL) of GIGA-2339(SAD: Pre-dose and at multiple timepoints post-dose up to Day 105; MAD: Pre-dose and at multiple timepoints post-dose up to Day 245)
- MAD: Serum Concentration at the End of the Dosing Interval (Ctrough) of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 245)
- MAD: AUC Versus Time Curve During the Dosing Interval (AUC0-tau) of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 245)
- MAD: Accumulation Ratio Cmax (ARCmax) of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 245)
- MAD: Accumulation Ratio AUC (ARAUCs) of GIGA-2339(Pre-dose and at multiple timepoints post-dose up to Day 245)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
1 期
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy ParticipantsHealthy VolunteersNCT04231513Eisai Inc.72
招募中
1 期
A Study of HS-10380 in Chinese ParticipantsSchizophreniaNCT05480592Jiangsu Hansoh Pharmaceutical Co., Ltd.76
已完成
1 期
Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's DiseaseAlzheimer's DiseaseNCT02434718Biogen21
Unknown
1 期
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy VolunteersHealthyNCT04652297Jiangsu Hansoh Pharmaceutical Co., Ltd.76
Unknown
1 期
Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.HealthyNCT04986436Jiangsu Hansoh Pharmaceutical Co., Ltd.76